Abeona Therapeutics (ABEO) Announces Publication of Positive EB-101 Phase 1 Data; Says Well-Tolerated in RDEB
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that positive clinical trial results from the EB-101 Phase I gene therapy clinical trial were published as "Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa" in the Journal of the American Medical Association (JAMA): http://jamanetwork.com/journals/jama/article-abstract/2576610. Abeona recently announced commencing enrollment in the Phase 2 portion of the clinical study (NCT01263379).
Typically, wounds in patients with RDEB, also known as "butterfly skin" syndrome, can remain unhealed for months to years due to the inability of the skin to stay attached to the underlying dermis and can cover a large percentage of the body. Results from the clinical study demonstrated that treatment with EB-101 restored Type VII collagen expression at the dermal-epidermal junction at the graft sites in 90% of the biopsy samples at 3 months post-treatment, in 66% at 6 months post-treatment, and in 42% samples at 12 months post-treatment. Importantly, correct type VII collagen localization was observed at anchoring fibrils. Wounds that demonstrated type VII collagen at graft sites displayed 87% healing at 3 months, 67% at 6 months, 50% at 12 months compared with baseline wound sites.
"Phase 1 data indicate that EB-101 COL7A1 ex-vivo gene transfer has a favorable safety profile and capable of cutaneous type C7 delivery, highlighting the potential of durable cell-based RDEB therapy in humans in devastating non-healing chronic wounds associated with high levels of morbidity and mortality," noted Steven H. Rouhandeh, Executive Chairman. "We are looking forward to completing Phase 2 enrollment and exploring approaches to make this potential breakthrough treatment available to RDEB patients."
The Phase 1 clinical trial with gene-corrected skin grafts has shown promising wound healing and safety in patients with RDEB. Investigators at Stanford University are enrolling adolescent and adult patients for the Phase 2 EB-101 trial to determine the safety and efficacy of COL7A1 gene-corrected grafts on wound healing.
"The clinical data demonstrate that EB-101 gene therapy corrected the underlying genetic deficit in RDEB patient wounds for months to over a year, and the wounds closed -- which is remarkable for a disease where the patient's skin can blister and erode every day," said Timothy J. Miller, Ph.D., President and CEO of Abeona Therapeutics. "We are very pleased that JAMA recognized the efforts of Drs. Peter Marinkovich, Jean Tang and the team at Stanford University for a decade of work and publish the clinical study results."
About Epidermolysis Bullosa (EB):
EB is a group of devastating, life-threatening genetic skin disorders impacting children that is characterized by skin blisters and erosions all over the body. The most severe form, recessive dystrophic epidermolysis bullosa (RDEB), is characterized by chronic skin blistering, open and painful wounds, joint contractures, esophageal strictures, pseudosyndactyly, corneal abrasions and a shortened life span. Patients with RDEB lack functional type VII collagen (C7) owing to mutations in the gene COL7A1 that encodes for C7 and is the main component of anchoring fibrils that attach the dermis to the epidermis. EB patients suffer through intense pain throughout their lives, with no effective treatments available to reduce the severity of their symptoms. Along with the life-threatening infectious complications associated with this disorder, many individuals often develop an aggressive form of squamous cell carcinoma (SCC).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abeona Therapeutics (ABEO) ABO-101 Gene Therapy Gains Orphan Drug Status in EU
- DryShips (DRYS) Acquires Its First VLGC With 5 Year Time Charter Attached to Oil Major
- ChemoCentryx (CCXI) Announces Presentation of Data from Ongoing Phase Ib Trial of CCR2 Inhibitor CCX872 at ASCO
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!